Clinical Trial Update: Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating NM8074 in patients with paroxysmal nocturnal hemoglobinuria who are already treated with Soliris; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• NM8074

Snippet

Sponsor: NovelMed Therapeutics | Conditions: PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: NOT_YET_RECRUITING